New hope for tough cancers: first test of experimental drug begins
NCT ID NCT05012618
Summary
This was an early-stage study to test a new cancer drug called LUNA18, given alone or with other cancer drugs, in people with advanced solid tumors that have spread or cannot be cured with standard treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for any early signs that it might help shrink tumors. The study was terminated early and did not move to later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, 19106, United States
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Beth Israel Deaconess
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National Cancer Center Hospital
Chuo-Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan
-
Renown Regional Medical Center
Reno, Nevada, 89502, United States
-
Rhode Island Hospital-Comprehensive Cancer Center
Providence, Rhode Island, 02903, United States
-
Shizuoka Cancer Center
Nakatogari, Shizuoka, 411-0934, Japan
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
University of California - Davis
Davis, California, 95616, United States
-
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.